PEPT (Regenerex Pharma) Net Income From Continuing Operations : $-3.63 Mil (TTM As of Jun. 2024)

View and export this data going back to . Start your Free Trial

What is Regenerex Pharma Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Regenerex Pharma's net income from continuing operations for the three months ended in Jun. 2024 was $-0.27 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2024 was $-3.63 Mil.

Regenerex Pharma Net Income From Continuing Operations Historical Data

The historical data trend for Regenerex Pharma's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenerex Pharma Net Income From Continuing Operations Chart

Regenerex Pharma Annual Data

Trend

Nov10

Nov11

Nov12

Nov13

Nov14

Mar17

Mar18

Mar22

Mar23

Mar24

Net Income From Continuing Operations

Get a 7-Day Free Trial

-0.05

-0.20

-0.14

-3.54

Regenerex Pharma Quarterly Data
	Nov14	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Net Income From Continuing Operations	Get a 7-Day Free Trial															-0.19	-2.80	-0.26	-0.29	-0.27

Regenerex Pharma Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.63 Mil.

Regenerex Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Regenerex Pharma Inc (OTCPK:PEPT) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

5348 Vegas Drive, Suite 177, Las Vegas, NV, USA, 89108

Website

https://regenerexpharmainc.com

Regenerex Pharma Inc develops and markets Woundcare Healing products. The current product technology provides the Company with a number of complete wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns, and surgical wounds. Its product Xcellderma OTC a Liquid Bandage Skin Protectant Xcellderma products are sterile wound dressings for treating diabetic foot ulcers, pressure ulcers, and other chronic wounds; Accelerex Sterile Wound Cream is for the treatment of a wide variety of chronic and acute wounds; and Accelerex Impregnated Sterile Wound Dressing use as a wound dressing to manage pressure ulcers (stages I-IV), stasis ulcers, diabetic skin ulcers, skin irritations, cuts, and abrasions.

Regenerex Pharma Headlines

No Headlines